Nathan Caffo
Corporate Officer/Principal presso CANDEL THERAPEUTICS, INC.
Profilo
Nathan Caffo is a professional who has worked in the biotech industry.
He is currently the Chief Business Officer at Candel Therapeutics, Inc. He previously worked as the President & Chief Executive Officer at Presage Biosciences, Inc. from 2009 to 2018, and as the Chief Business Officer at ALX Oncology Holdings, Inc. from 2018 to 2020.
Mr. Caffo received his undergraduate degree from The Pennsylvania State University.
Posizioni attive di Nathan Caffo
Società | Posizione | Inizio |
---|---|---|
CANDEL THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2020 |
Precedenti posizioni note di Nathan Caffo
Società | Posizione | Fine |
---|---|---|
ALX ONCOLOGY HOLDINGS INC. | Corporate Officer/Principal | 01/09/2020 |
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Chief Executive Officer | 17/07/2018 |
Formazione di Nathan Caffo
The Pennsylvania State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
CANDEL THERAPEUTICS, INC. | Health Technology |
ALX ONCOLOGY HOLDINGS INC. | Health Technology |
Aziende private | 1 |
---|---|
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Nathan Caffo